Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What will replace TURP?

M K Brawer1, J D McConnell, J E Oesterling

  • 1Department of Urology, University of Washington, Seattle.

Contemporary Urology
|January 9, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evidence: Non-metastatic prostate cancer.

The Western journal of medicine·2008
Same author

Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.

Reviews in urology·2006
Same author

Letter from the editors of reviews in urology.

Reviews in urology·2006
Same author

Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Reviews in urology·2006
Same author

Readership survey: reviews in urology.

Reviews in urology·2006
Same author

New urologic strategies explored at jackson hole: highlights from the 20th annual jackson hole urologic conference january 22-28, 2000, jackson hole, wyo.

Reviews in urology·2006

Benign prostatic hyperplasia (BPH) affects many men, with significant costs for surgical treatments like prostatectomy. This review identifies promising alternative therapies to transurethral resection of the prostate (TURP).

Area of Science:

  • Urology
  • Surgical Innovation
  • Health Economics

Background:

  • Benign prostatic hyperplasia (BPH) is a highly prevalent condition affecting a large percentage of men.
  • Current surgical treatments, such as transurethral resection of the prostate (TURP), incur substantial healthcare costs, exceeding $4 billion annually in the US.
  • Over 400,000 prostatectomies are performed each year, highlighting the significant clinical burden of BPH.

Purpose of the Study:

  • To address the intense interest in alternatives to traditional TURP for benign prostatic hyperplasia.
  • To identify and nominate emerging therapeutic options for BPH with high potential for success.
  • To provide an overview of promising BPH treatment alternatives for clinicians and researchers.

Main Methods:

  • Review of current literature on BPH treatments.

Related Experiment Videos

  • Panel nomination of leading alternative therapies.
  • Analysis of clinical impact and cost-effectiveness of emerging BPH interventions.

    • Main Results:

    • Benign prostatic hyperplasia (BPH) treatment is a major healthcare concern.
    • Significant financial investment is directed towards surgical interventions for BPH.
    • A variety of alternative treatments are being explored to improve BPH management.

    Conclusions:

    • The high prevalence and cost of BPH necessitate exploration of TURP alternatives.
    • Several promising alternative therapies are emerging for benign prostatic hyperplasia management.
    • Further evaluation of these alternatives is crucial for optimizing BPH patient care.